194 related articles for article (PubMed ID: 17979937)
1. Calcium supplements in patients with prostate cancer.
Molokwu CN
BJU Int; 2007 Dec; 100(6):1411. PubMed ID: 17979937
[No Abstract] [Full Text] [Related]
2. Nursing implications of androgen deprivation therapy-associated bone loss.
Weingard KK
Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
[TBL] [Abstract][Full Text] [Related]
3. Bone complications: an increasing risk in patients with prostate cancer.
J Support Oncol; 2007 Feb; 5(2):88-9. PubMed ID: 17348369
[No Abstract] [Full Text] [Related]
4. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
[No Abstract] [Full Text] [Related]
5. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
Izumi K; Mizokami A; Namiki M
Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
[TBL] [Abstract][Full Text] [Related]
6. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
McLeod N; Huynh CC; Rashid P
Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
[TBL] [Abstract][Full Text] [Related]
8. The if's, and's, or but's regarding bisphosphonates for prostate cancer.
Wilt TJ; Ensrud KE
J Natl Cancer Inst; 2007 May; 99(10):744-5. PubMed ID: 17505065
[No Abstract] [Full Text] [Related]
9. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
[TBL] [Abstract][Full Text] [Related]
10. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
11. Bone loss in prostate cancer: evaluation, treatment and prevention.
Saad F
Can J Urol; 2005 Feb; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
[TBL] [Abstract][Full Text] [Related]
12. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
Yaturu S; DjeDjos S; Alferos G; Deprisco C
Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
[TBL] [Abstract][Full Text] [Related]
14. Cancer treatment-induced bone loss.
Adler RA
Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
[TBL] [Abstract][Full Text] [Related]
15. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
[TBL] [Abstract][Full Text] [Related]
16. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
Roux C
Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
[No Abstract] [Full Text] [Related]
17. [Osteoporosis prophylaxis in men? Adverse effects of total androgen blockade in carcinoma of the prostate].
Hüfner M
Internist (Berl); 1999 Aug; 40(8):883. PubMed ID: 10476490
[No Abstract] [Full Text] [Related]
18. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.
Bruder JM
Curr Urol Rep; 2005 May; 6(3):157-8. PubMed ID: 15869718
[No Abstract] [Full Text] [Related]
19. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
20. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]